Sector News

GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots

October 22, 2014
Life sciences
With a three-part, multibillion-dollar transaction with Novartis set to close next year, changes are on the way for GlaxoSmithKline–and, fittingly, for its top management ranks, too.
 
At the center: R&D chief Moncef Slaoui will shift over to chair the vaccines unit–soon to be bolstered by a $7.1 buyout of most of the Swiss pharma’s vaccines portfolio–effective immediately. Patrick Vallance, who had run R&D on a day-to-day basis, will be stepping in to take the reins.
 
Slaoui, who radically altered the British drugmaker’s drug development process with a reorg focused on small units of scientists, “will take more focused accountability for vaccines, ensuring we fully leverage the value of his knowledge and experience,” a GSK spokeswoman Mary Anne Rhyne told FiercePharma by email.
 
The move is part of an effort to “ensure that our leaders are focused and aligned” around pharmaceuticals, vaccines and consumer healthcare–another business that will get a boost from the Novartis swap as the companies team up on a joint venture. GSK’s consumer health president, Emma Walmsley, will be heading up that partnership, with Glaxo controlling a 63.5% stake.
 
On the pharma side, emerging markets chief Abbas Hussain–who, if you’ll recall, last year publicly apologized to China’s government and offered price cuts in penance for the company’s $489 million doctor bribery scandal–will assume the role of global pharmaceuticals president, and he’ll have North American pharma president Dierdre Connelly reporting to him, Rhyne said.
 
And they’ll have their work cut out for them: In the third quarter, Glaxo reported pharmaceutical sales down 12% in the U.S., thanks in part to an 18% respiratory plunge. Megablockbuster Advair powered that decline, with increased competition helping take a 25% bite out of the aging behemoth’s top-line haul.
 
By Carly Helfand
 

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach